Loading
A phase 1/2 trial of Relatlimab + nivolumab, Pembrolizumab in melanoma, run by Krystal Biotech, Inc., now recruiting.
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05970497 by Krystal Biotech, Inc., with 240 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-07. Interventions recorded: KB707, Opdualag, KEYTRUDA ®( Pembrolizumab). Conditions listed: Cancer, Melanoma Stage III, Melanoma Stage IV, Cutaneous Melanoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Krystal Biotech, Pembrolizumab.
Shares Relatlimab + nivolumab, Melanoma.
Shares Relatlimab + nivolumab, Melanoma.
Shares Relatlimab + nivolumab, Pembrolizumab.
Shares Relatlimab + nivolumab, Melanoma.
Shares Relatlimab + nivolumab, Melanoma.
Shares Relatlimab + nivolumab, Melanoma.
Shares Relatlimab + nivolumab, Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/